According to Aimei Vaccine (06660), the company announced that on August 28, 2023, a randomized, double-blind, controlled trial of a 23-valent pneumococcal polysaccharide vaccine phase III was initiated at the disease control center of a southern county in Sichuan Province. This research will be conducted at two sites in Sichuan Province and one site in Shandong Province, planning to enroll 1,920 healthy subjects aged 2 or above.

Aimei Vaccine's application for clinical trials of the human rabies mRNA vaccine has recently been accepted by the Chinese drug regulatory authority (CDE). This marks the first domestically declared clinical application for a rabies mRNA vaccine.

On May 26th, the "Invest in Beijing Global Summit," hosted by the Beijing Municipal Government, was held at the Zhongguancun National Independent Innovation Demonstration Zone Exhibition Center. As a key investment attraction enterprise in the Beijing Economic and Technological Development Zone, Aimei Vaccine was invited to attend the summit and the signing ceremony for significant projects. As a leading domestic vaccine industry enterprise, Aimei Vaccine participated in the summit along with Fortune Global 500 companies, central enterprises, unicorn enterprises, fund companies, investment institutions, and other market entities.

On the morning of May 16th, the first pilot project in Guangdong, in which Aimei Vaccine participated, officially launched the Spark Project to eliminate the harm of viral hepatitis in Jun'an Town, Shunde District, Foshan City. The launch ceremony was held at the Zhipu Sports and Cultural Center in Hefeng Community, Jun'an Town. Aimei Vaccine donated 40,000 doses of hepatitis B vaccine for the free initial vaccination of the target population involved in the project. This project has attracted enthusiastic participation from local residents and has been referred to as a heartwarming and people-oriented project.

As International Labor Day arrived, Ran Lingfeng, the General Manager of Aimei Chengxin under Aimei Vaccines, was awarded the 2023 Liaoning Province May 1st Labor Medal. When flowers and applause were dedicated to the most admirable workers, Ran Lingfeng said she deeply felt the honor on her shoulders and would continue to carry forward the model worker spirit, forging the team's craftsmanship spirit to compose a new chapter for the innovative development of domestic vaccines!

The 2023 Northeast Three Provinces Vaccine Preventable Disease Prevention and Control Experience Exchange Meeting, organized by the Liaoning Provincial Society of Preventive Medicine, co-organized by Aimei Vaccines Co., Ltd. and Yunnan Watson Biotechnology Co., Ltd., and hosted by Dalian Jiuyi Biomedical Technology Co., Ltd., was successfully held in Dalian. The meeting focused on the exchange of experiences in the prevention and control of diseases such as hepatitis B, rabies, and cervical cancer. Aimei Vaccines' hepatitis B vaccine produced by Aimei Chengxin and Ningbo Rong'an, as well as the human rabies vaccine, received full recognition from the attending experts.

Another key product — quadrivalent meningococcal conjugate vaccine (MCV4) has been developed independently by AIM Vaccine. On March 15, the clinical test was officially carried out at Yanshan Disease Prevention and Control Center in Yunnan Province and related subjects were grouped.

Recently, AIM Vaccine’s bivalent Delta+ Omicron BA.5 mRNA COVID-19 vaccine under development was officially approved for Phase-III clinical test in Pakistan. The results of two clinical researches previously conducted in China indicate good safety, and the results of tests on live virus and antibody show that such vaccine under development can induce high-level neutralizing antibody against Delta, Omicron BA.5, BQ.1, and XBB variants of COVID-19 virus.

In the Notice on the First Adjustment of Hong Kong Stock Connect Targets after the Expansion of Shanghai-Hong Kong Connect Targets recently released by Shanghai Stock Exchange, AIM VACCINE (06660.HK) was incorporated into the first group of newly expanded Hong Kong Connect stocks under Shanghai-Hong Kong Connect Business. The Notice will take effect from March 13, 2023 (next Monday).